A gas, an amino acid, and an imposter: The story of nitric oxide, L-arginine, and ADMA in portal hypertension

Hepatology

Volumn 42, Issue 6, 2005, Pages 1255-1257

  Langer, Daniel A ^a   Shah, Vijay H ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ARGININE; N(G) NITROARGININE METHYL ESTER; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE;

CARDIOVASCULAR DISEASE; EDITORIAL; GAS; HUMAN; LIVER CIRRHOSIS; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROTEIN FUNCTION; VASOCONSTRICTION;

ANIMALS; ARGININE; HYPERTENSION, PORTAL; NITRIC OXIDE; RATS;

EID: 32944469163     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20989     Document Type: Editorial

References (27)

1. Bhathal PS, Grossman HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985;1:325-337.
2. Laleman W, Omasta A, Van de Casteele M, Zeegers M, Vander Elst I, Van Landeghem L, et al. A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis. HEPATOLOGY 2005;42:1382-1390.
3. Fiorucci S, Antonelli E, Morelli O, Mencarelli A, Casini A, Mello T, et al. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci U S A 2001;98:8897-8902.
4. Garcia-Pagan JC, Bosch J. The resistance of the cirrhotic liver: a new target for the treatment of portal hypertension. 1985. J Hepatol 2004;40:887-890.
5. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000;32:141-156.
6. Shah V. Cellular and molecular basis of portal hypertension. Clinics in Liver Disease 2001;5:629-644.
7. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. HEPATOLOGY 2002;35:478-491.
8. Kapoor D, Sarin SK. Pathophysiology of portal hypertension. J Gastroenterol Hepatol 2002;17(Suppl):S482-S487.
9. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998;114:344-351.
10. Dudenhoefer AA, Loureiro-Silva MR, Cadelina GW, Gupta T, Groszmann RJ. Bioactivation of nitroglycerin and vasomotor response to nitric oxide are impaired in cirrhotic rat livers. HEPATOLOGY 2002;36:381-385.
11. Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. HEPATOLOGY 1998;28:926-931.
12. Fiorucci S, Antonelli E, Mencarelli A, Orlandi S, Renga B, Rizzo G, Distrutti E, et al. The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis. HEPATOLOGY 2005;42:539-548.
13. Liu S, Premont RT, Kontos CD, Zhu S, Rockey DC. A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med 2005;11:952-958.
14. Morales-Ruiz M, Cejudo-Martn P, Fernandez-Varo G, Tugues S, Ros J, Angeli P, et al. Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats. Gastroenterology 2003;125:522-531.
15. Tran CT, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl 2003;4:33-40.
16. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004;24:1023-1030.
17. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113-2117.
18. Lluch P, Torondel B, Medina P, Segarra G, Del Olmo JA, Serra MA, Rodrigo JM. Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. J Hepatol 2004;41:55-59.
19. Mookerjee RP, Davies NA, Sen S, Hodges SJ, Turner C, Dalton RN, et al. Decreased hepatic extraction of asymmetric and symmetric dimethylarginine (ADMA/SDMA- NOS inhibitors) in acute alcoholic hepatitis may contribute to impaired end-organ function. HEPATOLOGY 2005;42:419A. Abstract 566.
20. Shah V, Toruner M, Haddad F, Cadelina G, Papapetropoulos A, Choo K, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 1999;117:1222-1228.
21. Nijveldt RJ, Teerlink T, Siroen MP, van Lambalgen AA, Rauwerda JA, van Leeuwen PA. The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin Nutr 2003;22:17-22.
22. Siroen MP, van der Sijp JR, Teerlink T, van Schaik C, Nijveldt RJ, van Leeuwen PA. The human liver clears both asymmetric and symmetric dimethylarginine. HEPATOLOGY 2005;41:559-565.
23. Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci U S A 1990;87:682-685.
24. Achan V, Tran CT, Arrigoni F, Whitley GS, Leiper JM, Vallance P. all-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase. Circ Res 2002;90:764-769.
25. Tojo A, Welch WJ, Bremer V, Kimoto M, Kimura K, Omata M, et al. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 1997;52:1593-1601.
26. Scalera F, Borlak J, Beckmann B, Martens-Lobenhoffer J, Thum T, Tager M, et al. Endogenous nitric oxide synthesis inhibitor asymmetric dimethyl L-arginine accelerates endothelial cell senescence. Arterioscler Thromb Vasc Biol 2004;24:1816-1822.
27. Mishima T, Hamada T, Ui-Tei K, Takahashi F, Miyata Y, Imaki J, et al. Expression of DDAH1 in chick and rat embryos. Brain Res Dev Brain Res 2004;148:223-232.